Iovance Biotherapeutics, Inc.
8.43USD
-0.2700 (-3.10%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | — | 1.2M | 164.1M | 263.5M | 401.5M | 557.4M |
| Q1 | — | — | 715.0K | 49.3M | 71.4M | — |
| Q2 | — | 238.0K | 31.1M | 60.0M | 99.3M | — |
| Q3 | — | 469.0K | 58.6M | 67.5M | 110.1M | — |
| Q4 | — | 482.0K* | 73.7M* | 86.8M* | 120.7M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -2.49 | -1.89 | -1.28 | -1.09 | -.496 | -.287 |
| Q1 | -572.46 | -454.50 | -.420 | -.360 | -.190 | — |
| Q2 | -622.44 | -.470 | -.340 | -.330 | -.110 | — |
| Q3 | -624.33 | -.460 | -.280 | -.250 | -.096 | — |
| Q4 | -661.31* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| -494.95* |
| -271.01* |
| -201.22* |
| -.106 |
| — |